Get notified when NKTR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Class Action Lawsuit (new) — The company disclosed a new securities class action lawsuit alleging misleading statements regarding the REZOLVE-AA trial.
- Newly Disclosed Significant Litigation (new) — In March 2026, a putative class action complaint was filed in the U.S. District Court for the Northern District of California against the Company, our CEO, our former CFO and our Chief Research and Development Officer, captioned Schramke v. Nektar Therapeutics, et al.
- New Putative Class Action Lawsuit (new) — In March 2026, a putative class action complaint was filed in the U.S. District Court for the Northern District of California against the Company, our CEO, our former CFO and our Chief Research and Development Officer, captioned Schramke v. Nektar Therapeutics, et al. The complaint asserts claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC rules promulgated thereunder, seeks damages, attorneys' fees and other relief, and alleges, among other things, that from February 2025 through December 2025, the defendants made misleading statements and/or failed to disclose material information regarding the REZOLVE-AA trial.
Nektar Therapeutics reported a net loss of $40.6M for the second quarter, narrowed from $41.6M a year earlier, while advancing rezpegaldesleukin into Phase 3 registrational trials.
Filed August 14, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 8, 2025 · ~1 min read
Key Changes
-
medium
A new putative securities class action lawsuit was filed in March 2026 against the Company and certain officers, alleging misleading statements regarding the REZOLVE-AA trial; the Company denies the claims and intends to defend vigorously.
-
low
Revenue fell 9.3% to $10.1M in the second quarter, consisting entirely of non-cash royalty revenue related to the sales of future royalties.
-
medium
Research and development expense rose 30.9% to $39.1M in the second quarter, which the company attributes to activities to support the Phase 3 ZENITH AD program in atopic dermatitis, including clinical trial start-up activities with our contract research organizations, and manufacturing activities associated with rezpegaldesleukin.
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (DPZ 10-Q) is open in full — no account needed.
Partner
Trade NKTR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 17, 2026 · How we verify